Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) CFO Sells 10,564 Shares of Stock

Key Points

• CFO Vishwas Setia sold 10,564 shares on May 6 at an average price of $28.24 for $298,327, executing under a pre‑arranged Rule 10b5‑1 trading plan; he still owns 356,256 shares after the sale (a 2.88% reduction, valued at ≈$10.06M).
• The stock traded up about 4.0% to $29.04 on the day of the filing (267,979 shares traded) while Maplight has a market cap near $1.24B and a 50‑day moving average of $22.60.
• Company fundamentals and analyst views are mixed: Maplight posted a sizable Q1 EPS miss (‑$2.47 vs. ‑$1.05 consensus), but analysts hold a "Moderate Buy" average with a $34.43 price target and several recent buy initiations (e.g., HC Wainwright, Needham).

Maplight Therapeutics, Inc. (NASDAQ:MPLT - Get Free Report) CFO Vishwas Setia sold 10,564 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $28.24, for a total transaction of $298,327.36. Following the sale, the chief financial officer owned 356,256 shares in the company, valued at $10,060,669.44. This represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vishwas Setia also recently made the following trade(s):

• On Tuesday, May 5th, Vishwas Setia sold 10,903 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.20, for a total transaction of $307,464.60.
• On Monday, May 4th, Vishwas Setia sold 14,904 shares of Maplight Therapeutics stock. The stock was sold at an average price of $28.11, for a total transaction of $418,951.44.

Maplight Therapeutics Trading Up 4.0%

Shares of NASDAQ MPLT traded up $1.12 during trading hours on Wednesday, hitting $29.04. 267,979 shares of the stock were exchanged, compared to its average volume of 342,018. The firm has a market cap of $1.24 billion and a P/E ratio of -0.73. The firm has a fifty day moving average of $22.60. Maplight Therapeutics, Inc. has a 1-year low of $12.24 and a 1-year high of $33.28.

Maplight Therapeutics (NASDAQ:MPLT - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($2.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($1.42). Equities analysts anticipate that Maplight Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on MPLT shares. Canaccord Genuity Group started coverage on shares of Maplight Therapeutics in a research note on Thursday, March 19th. They issued a "buy" rating and a $35.00 price objective for the company. Weiss Ratings started coverage on shares of Maplight Therapeutics in a research note on Thursday, January 22nd. They issued a "sell (e)" rating for the company. TD Cowen started coverage on shares of Maplight Therapeutics in a research note on Tuesday, April 7th. They issued a "buy" rating for the company. Wall Street Zen downgraded shares of Maplight Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, March 21st. Finally, HC Wainwright started coverage on shares of Maplight Therapeutics in a research note on Monday. They issued a "buy" rating and a $45.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Maplight Therapeutics has an average rating of "Moderate Buy" and an average price target of $34.43.

Hedge Funds Weigh In On Maplight Therapeutics

Large investors have recently modified their holdings of the business. Strs Ohio bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $70,000. New York State Common Retirement Fund bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $93,000. MetLife Investment Management LLC bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $172,000. Finally, Walleye Capital LLC bought a new position in shares of Maplight Therapeutics during the fourth quarter valued at $205,000.

Key Maplight Therapeutics News

Here are the key news stories impacting Maplight Therapeutics this week:

• Positive Sentiment: Needham reaffirmed its "Buy" rating on MPLT, signaling continued analyst conviction that the shares have upside. Needham Reaffirms Buy
• Positive Sentiment: HC Wainwright initiated/updated coverage with a "Buy" rating and a $45 price target (roughly mid‑50% upside from recent levels), which can attract buyers and support the rally. Many outlets reported the new coverage and target. HC Wainwright Coverage & Target
• Neutral Sentiment: Morningstar and market quote pages show current trading context (price, volume, 50‑day moving average) that traders use to gauge technical support/resistance. Use these pages for up‑to‑date quotes. Morningstar Quote
• Negative Sentiment: HC Wainwright's detailed forecasts also project larger net losses over 2026–2027 (FY2026 EPS ~ -$4.34; FY2027 EPS ~ -$5.25) and quarterly losses through 2027 — data that underscores continued cash‑burn and execution risk for a clinical‑stage biotech. This raises downside risk if clinical or financing progress stalls. Analyst Estimates
• Negative Sentiment: Recent reported results included a sizable Q1 EPS miss (reported -$2.47 vs. consensus -$1.05), which remains a reminder of earnings volatility and could pressure sentiment if follow‑up data or guidance are weak. Recent Earnings Miss

Maplight Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.